Role and interpretation of fluorodeoxyglucose-positron emission tomography/computed tomography in HIV-infected patients with fever of unknown origin: A prospective study

HIV Medicine

Volumn 14, Issue 8, 2013, Pages 455-462

  Martin, C ^a   Castaigne, C ^a,b   Tondeur, M ^a   Flamen, P ^b   De Wit, S ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b IRIS   (Belgium)

Author keywords

Fever of unknown origin; HIV; Positron emission tomography computed tomography; Viraemia

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE; LYMPH NODE BIOPSY; MALE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; SENSITIVITY AND SPECIFICITY; VIREMIA;

FEVER OF UNKNOWN ORIGIN; HIV; POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; VIRAEMIA;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; FEVER OF UNKNOWN ORIGIN; FLUORODEOXYGLUCOSE F18; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84881314138     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12030     Document Type: Article

References (29)

1. Miralles P, Moreno S, Perez-Tascon M, Cosin J, Diaz MD, Bouza E. Fever of uncertain origin in patients infected with the human immunodeficiency virus. Clin Infect Dis 1995; 20: 872-875.
2. Armstrong WS, Katz JT, Kazanijan PH. Human immunodeficiency virus-associated fever of unknown origin: a study of 70 patients in the United States and review. Clin Infect Dis 1999; 28: 341-345.
3. Kitkungvan D, Apisarnthanarak A, Plengpart P, Mundy LM. Fever of unknown origin in patients with HIV infection in Thailand. Int J STD AIDS 2008; 19: 232-235.
4. Sathekge M, Maes A, Al-Nahhas A, Rubello D, Chiti A. What impact can fluorine-18 FDG PET/CT have on HIV/AIDS and tuberculosis pandemic? Nucl Med Comm 2009; 30: 255-257.
5. Glaudemans W, Signore A. FDG-PET/CT in infections: the imaging method of choice? Eur J Nucl Med Mol Imaging 2010; 37: 1986-1991.
6. Balink H, Collins J, Bruyn G, Gemmel F. F-18 FDG-PET/CT in the diagnosis of fever of unknown origin. Clin Nucl Med 2009; 34: 862-868.
7. Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of Unknown Origin: the role of FDG-PET/CT. J Nucl Med 2008; 49: 1980-1985.
8. Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 2007; 48: 35-45.
9. Kumar R, Basu S, Torigian D, Anand V, Zhuang H, Alavi A. Role of modern imaging techniques for diagnosis of infection in the era of FDG-PET/CT. Clin Microbio Rev 2008; 21: 209-224.
10. Bleeker-Rovers CP, van der Meer JW, Oyen WJ. Fever of unknown origin. Semin Nucl Med 2009; 39: 81-87.
11. Castaigne C, Tondeur M, De Wit S, Hildebrand M, Clumeck N, Dusart M. Clinical value of FDG-PET/CT for the diagnosis of HIV-associated fever of unknown origin: a retrospective study. Nucl Med Comm 2009; 30: 41-47.
12. O'Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the HIV-positive patient. J Nucl Med 1997; 38: 1575-1583.
13. Sathekge M, Maes A, Kgomo M, Stoltz A, Pottel H, Van de Wiele C. Impact of FDG-PET on the management of tuberculosis treatment. Nuklearmedizin 2010; 49: 35-40.
14. Liu RS, Shei HR, Chu YK, Feng CF, Su WJ. Detection of extrapulmonary tuberculosis with F-18 FDG-PET Rev. Med Nucl Alasbinm J 2002; 17: 504.
15. Harisankar CNB, Mittal BR, Bhattacharya A, Singh B. FDG-PET/CT in diagnosis and early response evaluation of extrapulmonary tuberculosis in a patient with aplastic anemia. J Postgrad Med 2010; 56: 219-221.
16. Sathekge M, Goethals I, Maes A, van de Wiele C. Positron emission tomography in patients suffering from HIV-1 infection. Eur J Nucl Med Mol Imaging 2009; 36: 1176-1184.
17. Sathekge M, Maes A, Kgomo M, Van de Wiele C. FDG uptake by lymph nodes of HIV patients is inversely related to CD4 count. Nucl Med Comm 2010; 31: 137-140.
18. Brust D, Polis M, Davey R etal. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 2006; 20: 985-993.
19. Iyengar S, Chin B, Margolick J, Beulach P, Schwartz D. Anatomical loci of HIV-associated immune activation and association with viremia. Lancet 2003; 20: 945-950.
20. Scharko A, Perlman S, Pyzalski R, Graziano F, Sosman J, Pauza C. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet 2003; 20: 959-961.
21. Lucignani G, Orunesu E, Cesari M etal. FDG-PET/CT imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging 2009; 36: 640-647.
22. Goshen E, Davidson T, Avigdor A, Zwas T, Levy I. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med 2008; 33: 610-614.
23. Bhargava P, Chang CW, Glickman B, Sara G, Ghesani M. Persistent generalized lymphadenopathy (PGL) mimicking lymphoma on whole-body FDG PET/CT imaging. Clin Nucl Med 2006; 31: 398-400.
24. Barker R, Kazmi F, Stebbing J etal. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease. Eur J Nucl Med Mol Imaging 2009; 36: 648-652.
25. Murphy SP, Nathan MA, Karwal MW. FDG-PET appearance of pelvic Castleman's disease. J Nucl Med 1997; 38: 1211-1212.
26. Cazaentre T, Sanhes L, Laurent G, Costa K, Vallantin X, Pascal-Ortiz D. Assessment of plasmablastic lymphoma by F-FDG PET/CT. Clin Nucl Med 2010; 35: 882-883.
27. Bleeker-Rovers CP, De Kleijn E, Corstens FHM, Van der Meer JW, Oyen WJ. Clinical value of FDG-PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging 2004; 31: 29-37.
28. Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 2000; 27: 822-832.
29. Tabor PA. Drug-induced fever. Drug Intell Clin Pharm 1986; 20: 413-420.